Seema_bansal

Seema bansal

Dr. Seema Bansal, Associate Scientific Director, Gene Delivery, Process and Analytical Development, Cell Therapy Development at Bristol Myers Squibb. CMC-matrix team lead with over 8 years of industry experience in multiple therapeutics modalities including Mabs, vaccines, peptide conjugates and AAV/LVV based CAR-T cell therapies. With BMS since 2021 leading CAR-T Vector Analytical Strategy from development to commercialization through life cycle management. Strategic CMC team lead driving establishment of LVV CQAs/ ATPs and phase appropriate analytical strategies with key emphasis on vector potency, reference standard, justification of specifications and analytical comparability. Enabling critical program development activities with CMOs, CTLs, CROs and serving as a technical expert for viral vector and gene delivery programs facilitating regulatory submissions across multiple jurisdictions. Prior experience with Janssen from phase 1 to phase 3 modalities in analytical development focused on key areas of bioassay method development, product characterization, phase-appropriate analytical method qualification/validation and method transfers in compliance with GMP SOPs and regulatory requirements. Academic experience spanned from enzyme purification, mitochondrial targeting of Cytochrome P-450 and understanding of molecular mechanism underlying dual targeting elucidating P450s role in carcinogenesis and alcohol toxicity. Authored more than 20 scientific manuscripts in peer reviewed journals, six-sigma green belt certified and passionate about bringing novel therapeutics to meet patient un-met needs.


Appearances